- 询价
- 晶抗生物
- JK164242
- 上海
- 2025年09月09日
- 科研试验
- Rabbit
- Human,Mouse,Rat,Chicken,Dog,Cow,Rabbit,Sheep
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
上海晶抗生物工程有限公司
- 库存：
大量
- 克隆性：
多克隆
- 保质期：
1年
- 抗体英文名：
Anti-IL36B antibody
- 宿主：
Rabbit
- 适应物种：
Human,Mouse,Rat,Chicken,Dog,Cow,Rabbit,Sheep
- 应用范围：
科研试验
- 保存条件：
-20°C
- 规格：
25 μl/100 μl/200 μl
Cat. No. JK164242
Package 25 μl/100 μl/200 μl
Storage -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Product overview
Description Anti-IL36B rabbit polyclonal antibody
Applications ELISA, IHC
Immunogen Synthetic peptide of human IL36B
Reactivity Human
Content 0.78 mg/ml
Host species Rabbit
Ig class Immunogen-specific rabbit IgG
Purification Antigen affinity purification
Target information
Symbol IL36B
Full name interleukin 36 beta
Synonyms FIL1; FIL1H; IL1F8; IL1H2; IL-1F8; IL-1H2; IL1-ETA; FIL1-(ETA); FILI-(ETA)
Swissprot Q9NZH7
Target Background
The protein encoded by this gene is a member of the interleukin 1 cytokine family. Protein structure modeling indicated that this cytokine may contain a 12-stranded beta-trefoil structure that is conserved between IL1A (IL-A alpha) and IL1B (IL-1 beta). This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. Two alternatively spliced transcript variants encoding distinct isoforms have been reported.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Genotyping Anti-Hepatitis B Virus Drug Resistance
Agents available or in development for the treatment of chronic hepatitis B virus (HBV) infection fall into two major groups: immunomodulators, such as interferon-α and therapeutic vaccines, and nucleoside/nucleotide analogs
Induction of Anti-Hepatitis B Virus Immune Responses Through DNA Immunization
Cellular and humoral immune responses to different hepatitis B virus (HBV) antigens are believed to play an essential role in the elimination of virus by the host. It is well established that the humoral immune response to HBV envelope
Designing Clinical Development Programs for Anti-Hepatitis B Virus Drugs
Hepatitis B virus (HBV) infection remains one of the leading infectious causes of chronic liver disease and death in the world (1 ,2 ). With the advent of universal HBV vaccination and with the availability of antiviral therapeutics, HBV
